Poland· PL-100381766
Glyxambi
A linagliptin and empagliflozin product containing empagliflozinum + linagliptinum, registered in Poland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Linagliptin and empagliflozin is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BD19 (linagliptin and empagliflozin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Linagliptin and empagliflozin · ATC A10BD19
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Empagliflozinum + Linagliptinum
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Poland (PL)
- ATC code
- A10BD19
- ATC class
- Linagliptin and empagliflozin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 9
- gtin05909991308544
- gtin05909991308551
- gtin05909991308568
- gtin05909991308605
- gtin05909991308612
- gtin05909991308629
- gtin05909991308575
- gtin05909991308582
- gtin05909991308599
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linagliptin and empagliflozin in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLYXAMBIBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- United StatesGlyxambiBoehringer Ingelheim Pharmaceuticals, Inc.
- SpainGLYXAMBI 10 MG/5 MG COMPRIMIDOS RECUBIERTOS CON PELICULABoehringer Ingelheim International Gmbh
- FinlandGlyxambiBoehringer Ingelheim International GmbH
- United KingdomGlyxambi 10mg/5mg tabletsBoehringer Ingelheim Ltd
- IrelandGlyxambi 10 mg/5 mg film-coated tabletsBoehringer Ingelheim International GmbH
- IcelandGlyxambiBoehringer Ingelheim International GmbH*
- NetherlandsGlyxambi 10 mg/ 5 mg, filmomhulde tablettenBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Glyxambi
- Liechtenstein · Glyxambi
- Norway · Glyxambi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4cbb2566-252f-4b89-8d66-43870fea2e08 GET /v1/drugs/4cbb2566-252f-4b89-8d66-43870fea2e08?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "10 mg + 5 mg",
"packaging": "05909991308544 ¦ Rp ¦ EU/1/16/1146/001 ¦ 119368\n7 tabl.\n05909991308551 ¦ Rp ¦ EU/1/16/1146/002 ¦ 119369\n10 tabl.\n05909991308568 ¦ Rp ¦ EU/1/16/1146/003 ¦ 119370\n14 tabl.\n05909991308575 ¦ Rp ¦ EU/1/16/1146/004 ¦ 119371\n28 tabl.\n05909991308582 ¦ Rp ¦ EU/1/16/1146/005 ¦ 119372\n30 tabl.\n05909991308599 ¦ Rp ¦ EU/1/16/1146/006 ¦ 119373\n60 tabl.\n05909991308605 ¦ Rp ¦ EU/1/16/1146/007 ¦ 119374\n70 tabl.\n05909991308612 ¦ Rp ¦ EU/1/16/1146/008 ¦ 119375\n90 tabl.\n05909991308629 ¦ Rp ¦ EU/1/16/1146/009 ¦ 119376\n100 tabl.",
"substance": "Empagliflozinum 10 mg + Linagliptinum 5 mg",
"common_name": "Empagliflozinum + Linagliptinum",
"pl_product_id": "100381766",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about linagliptin and empagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.